304 related articles for article (PubMed ID: 30114235)
1. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced parotid changes in oropharyngeal cancer patients: the role of early functional imaging and patient-/treatment-related factors.
Marzi S; Farneti A; Vidiri A; Di Giuliano F; Marucci L; Spasiano F; Terrenato I; Sanguineti G
Radiat Oncol; 2018 Oct; 13(1):189. PubMed ID: 30285893
[TBL] [Abstract][Full Text] [Related]
3. Histogram analysis parameters identify multiple associations between DWI and DCE MRI in head and neck squamous cell carcinoma.
Meyer HJ; Leifels L; Schob S; Garnov N; Surov A
Magn Reson Imaging; 2018 Jan; 45():72-77. PubMed ID: 28963049
[TBL] [Abstract][Full Text] [Related]
4. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
[TBL] [Abstract][Full Text] [Related]
5. Unified platform for multimodal voxel-based analysis to evaluate tumour perfusion and diffusion characteristics before and after radiation treatment evaluated in metastatic brain cancer.
Coolens C; Driscoll B; Foltz W; Svistoun I; Sinno N; Chung C
Br J Radiol; 2019 Apr; 92(1096):20170461. PubMed ID: 30235004
[TBL] [Abstract][Full Text] [Related]
6. Combined diffusion-weighted, blood oxygen level-dependent, and dynamic contrast-enhanced MRI for characterization and differentiation of renal cell carcinoma.
Notohamiprodjo M; Staehler M; Steiner N; Schwab F; Sourbron SP; Michaely HJ; Helck AD; Reiser MF; Nikolaou K
Acad Radiol; 2013 Jun; 20(6):685-93. PubMed ID: 23664397
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.
Anzidei M; Napoli A; Sacconi B; Boni F; Noce V; Di Martino M; Saba L; Catalano C
Radiol Med; 2016 Dec; 121(12):905-915. PubMed ID: 27567615
[TBL] [Abstract][Full Text] [Related]
8. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
9. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
10. Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy.
Reynolds HM; Tadimalla S; Wang YF; Montazerolghaem M; Sun Y; Williams S; Mitchell C; Finnegan ME; Murphy DG; Haworth A
Cancer Imaging; 2022 Dec; 22(1):71. PubMed ID: 36536464
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
12. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted imaging for assessment of synovial inflammation in juvenile idiopathic arthritis: a promising imaging biomarker as an alternative to gadolinium-based contrast agents.
Barendregt AM; van Gulik EC; Lavini C; Nusman CM; van den Berg JM; Schonenberg-Meinema D; Dolman KM; Kuijpers TW; Hemke R; Maas M
Eur Radiol; 2017 Nov; 27(11):4889-4899. PubMed ID: 28608162
[TBL] [Abstract][Full Text] [Related]
14. Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments.
Zhang Y; Kapur P; Yuan Q; Xi Y; Carvo I; Signoretti S; Dimitrov I; Cadeddu JA; Margulis V; Muradyan N; Brugarolas J; Madhuranthakam AJ; Pedrosa I
Clin Genitourin Cancer; 2016 Feb; 14(1):e25-36. PubMed ID: 26422014
[TBL] [Abstract][Full Text] [Related]
15. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
16. Detectability of radiation-induced changes in magnetic resonance biomarkers following stereotactic radiosurgery: A pilot study.
Winter JD; Moraes FY; Chung C; Coolens C
PLoS One; 2018; 13(11):e0207933. PubMed ID: 30475887
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response.
Mytsyk Y; Pasichnyk S; Dutka I; Dats I; Vorobets D; Skrzypczyk M; Uteuliyev Y; Botikova A; Gazdikova K; Kubatka P; Urdzik P; Kruzliak P
Clin Exp Med; 2020 May; 20(2):277-287. PubMed ID: 32026157
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
19. Short-term follow-up MRI after unplanned resection of malignant soft-tissue tumours; quantitative measurements on dynamic contrast enhanced and diffusion-weighted MR images.
Kim JI; Lee IS; Song YS; Park SK; Choi KU; Song JW
Br J Radiol; 2016 Oct; 89(1066):20160302. PubMed ID: 27459249
[TBL] [Abstract][Full Text] [Related]
20. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
